PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.

CONCLUSION: Our results suggest that the PD-L1 and IDO1 immune checkpoint inhibitors may provide clinical benefit in osteosarcoma patients with metastatic lesions after conventional chemotherapy.
PMID: 32388585 [PubMed - as supplied by publisher]

Source: Clin Med Res - May 8, 2020 Category: Research Authors: Toda Y, Kohashi K, Yamada Y, Yoshimoto M, Ishihara S, Ito Y, Iwasaki T, Yamamoto H, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y Tags: J Cancer Res Clin Oncol Source Type: research